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ABSTRACT
Objectives: Cardiac surgery with cardiopulmonary bypass and cardioplegic ar-
rest is an effective treatment for coronary artery and aortic valve diseases. How-
ever, the myocardium sustains reperfusion injury after ischemic cardioplegic
arrest. Our objective was to assess the benefits of supplementing cardioplegia so-
lution with the general anesthetic propofol in patients undergoing either coronary
artery bypass grafting (CABG) or aortic valve replacement (AVR).
Methods: A single-center, double-blind randomized controlled trial was carried
out to compare cardioplegia solution supplemented with propofol (concentration
6 mg/mL) versus intralipid (placebo). The primary outcome was cardiac troponin
T release over the first 48 hours after surgery.
Results:We recruited 101 participants (51 in the propofol group, 50 in the intra-
lipid group); 61 underwent CABG and 40 underwent AVR. All participants were
followed to 3 months. Cardiac troponin T release was on average 15% lower with
propofol supplementation (geometric mean ratio, 0.85; 95% confidence interval
[CI], 0.73-1.01; P ¼ .051). There were no differences for CABG participants but
propofol-supplemented participants undergoing AVR had poorer postoperative
renal function (geometric mean ratio, 1.071; 95% CI, 1.019-1.125; P ¼ .007),
with a trend toward longer intensive care stay (median, 89.5 vs 47.0 hours; hazard
ratio, 0.58; 95% CI, 0.31-1.09; P ¼ .09) and fewer with perfect health (based on
the EQ-5D health utility index) at 3 months (odds ratio, 0.26; 95% CI, 0.06-1.05;
P ¼ .058) compared with the intralipid group. Safety profiles were similar. There
were no deaths.
Conclusions: Propofol supplementation in cardioplegia appears to be cardiopro-
tective. Its influence on early clinical outcomes may differ between CABG and
AVR surgery. A larger, multicenter study is needed to confirm or refute these sug-
gestions. (J Thorac Cardiovasc Surg 2015;150:1610-9)
Cardiac troponin T level over time, expressed as geo-
metric mean ratio (GMR) (95% confidence interval)
for propofol versus intralipid (placebo).
Central Message
Cardioplegia supplemented with propofol ap-
pears to be cardioprotective (ie, lower cardiac
troponin level) in patients undergoing CABG
or AVR surgery.
Perspective
This first randomized trial comparing cardiople-
gia supplemented with propofol versus intrali-
pid suggests propofol may be cardioprotective
in patients undergoing CABG or AVR (average
15% reduction in troponin T release during the
first 48 hours after surgery). Its influence on
early clinical outcomes may differ between
CABG and AVR. A larger study is needed to
confirm or refute these findings.
See Editorial Commentary page 1620.
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Myocardial protection with cardioplegic arrest remains the
most popular technique during cardiac surgery with cardio-
pulmonary bypass (CPB). However, this intervention renders
the heart globally ischemic and therefore susceptible to the
damaging effects of reperfusion.1,2 Key events emanating
from an ischemic insult include disruption to metabolic and
ionic homeostasis.3 During ischemia, anaerobic metabolism
leads to buildup of lactic acid (intracellular acidosis), which
in turn causes a rise in intracellular sodium ion concentration
via the sodium ion/hydrogen ion exchanger. Moreover, pro-
longed ischemia can also lead to calcium ion loading via
the sodium ion/calcium ion exchanger. In addition to causing
calcium ion loading, the ischemia-induced sodium ion accu-
mulation could also contribute to osmotic-induced cell
swelling, which can cause sarcolemmal damage.4-6 Upon
reperfusion the renewed supply of oxygen leads to a surge
in the formation of mitochondrial reactive oxygen species,
as well as further significant calcium ion loading, both of
which cause cardiomyocyte death by necrosis and
apoptosis.7,8 It is now established that this reperfusion
injury is mediated by the opening of the mitochondrial
permeability transition pore (mPTP), which is triggered
by calcium ion overload and oxidative stress.9-11 A
consequence of reperfusion injury is the recruitment of
macrophages and neutrophils to the necrotic area, causing
further damage to surrounding tissue.12,13 In view of the
suboptimal protection conferred by current cardioplegic
techniques, additional components have been sought that
can reduce reactive oxygen species generation and calcium
ion loading or, ultimately, inhibit the opening of mPTP.14
Propofol is widely used for the induction and maintenance
of anesthesia during cardiac surgery.15 In addition to its anes-
thetic effect, extensive studies in animalmodels have demon-
strated that direct coronary perfusion with propofol is
cardioprotective during coronary reperfusion16 and such pro-
tection is mediated by improving tissue antioxidant capacity
and reducing lipid peroxidation.17 Protection has been shown
in patients with diabetes18 and with hypertrophic19 hearts.
More importantly, a study in 2000 demonstrated that propo-
fol at a clinically relevant concentration confers significant
protection against global normothermic ischemia and during
cold cardioplegic arrest, and that this effect was associated
with less opening of mPTP.20 Moreover, the vehicle, intrali-
pid, does not seem to be cardioprotective.20,21 Finally, a
clinically relevant model has been used to support the
inclusion of propofol in cardioplegia,22 prompting the design
of this clinical trial to investigate its efficacy.
This study extends this work to a human clinical setting;
the Propofol cardioplegia for Myocardial Protection
(ProMPT) trial aims to test the hypothesis that supplemen-
tation of the cardioplegic solution with propofol is cardio-
protective for patients undergoing isolated coronary artery
bypass grafting (CABG) or aortic valve replacement (AVR).
METHODS
Trial Design
The ProMPT trial is a single-center, double-blind, parallel-group,
placebo-controlled randomized controlled trial. Participants were
randomly allocated to propofol or intralipid (placebo) supplementation in
a 1:1 ratio. This clinical trial is registered with Current Controlled Trials
(http://www.controlled-trials.com/ISRCTN84968882).
Participants
Adults (aged18 and80 years) undergoing elective or urgent isolated
CABG or AVR surgery with CPB were eligible to participate. Patients who
had undergone previous surgery, were having combined CABG and AVR,
an emergency or salvage operation, or were participating in another clinical
trial were excluded. Patients with chronic renal failure requiring dialysis,
congestive heart failure, poor left ventricular function, or an allergy to
either propofol or intralipid were also excluded.
The study was conducted at the Bristol Heart Institute, a specialized
regional cardiac surgery center in the United Kingdom. The study was
approved by the West Midlands Research Ethics Committee (reference
No. 09/H1208/60) and by the Medicines and Healthcare Products Regula-
tory Authority (Eudract: 2009-015779-28).
Interventions
Eligible patients (all under the care of a single surgeon [A.J.B.]) were ran-
domized to cardioplegia supplementation with either propofol (at a concen-
tration of 6 mg/mL) or intralipid. A propofol concentration of 6 mg/mL does
not exceed the level routinely observed in the circulation during induction or
maintenance of anesthesia for cardiac surgery.23 The stock propofol (10,000
mg/mLFresenius Propoven 1% emulsion; FreseniusKabi, Uppsala, Sweden)
was diluted as recommended by the manufacturer to achieve a working
solution of 2000 mg/mL. The intralipid emulsion (Fresenius 10%), was
diluted in the same manner.
Warm blood cardioplegia (Calafiore formulation) with intermittent an-
tegrade delivery was used for participants undergoing isolated CABG, and
cold blood cardioplegia (Harefield Hospital formulation; Ivex Pharmaceu-
ticals, Antrim, Northern Ireland) with either intermittent antegrade or ante-
grade and retrograde delivery was used for participants having AVR23 (see
the Online Data Supplement for details). For participants undergoing iso-
lated CABG, supplementation (propofol or equivalent volume of intralipid)
was implemented by attaching an additional syringe pump to the line
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CPB ¼ cardiopulmonary bypass
cTNT ¼ cardiac troponin T
ICU ¼ intensive care unit
GMR ¼ geometric mean ratio
MLHFQ ¼ Minnesota Living with Heart Failure
Questionnaire
mPTP ¼ mitochondrial permeability transition
pore
SAE ¼ serious adverse event
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downstream of the blood oxygenator, with the syringe driver set to 0.6 mL/
min resulting in a 6 mg/mL supplementation of the blood/cardioplegia mix
during delivery. For participants undergoing isolated AVR the supplemen-
tation was added directly to a 500-mL bag of 4:1 blood:cardioplegia solu-
tion. Information on propofol clearance is reported elsewhere.23
Anesthetic management adhered strictly to a locally agreed-upon proto-
col, and all other aspects of the patient’s pre- and postoperative manage-
ment was in accordance with existing protocols (see the Online Data
Supplement and published descriptions24,25 for further details).
Outcomes
The primary outcome was myocardial injury, assessed by cardiac
troponin T (cTnT) in serum from blood samples collected preoperatively
and at 1, 6, 12, 24, and 48 hours after chest closure. Secondary outcomes
were myocardial ischemic stress assessed in biopsies taken from left and
right ventricles; systemic metabolic stress assessed by lactate; blood pH;
serum creatinine level; plasma propofol concentration; length of intensive
care unit (ICU)/high dependency unit stay; clinical outcomes and serious
adverse events (SAEs) to 3 months postsurgery; and patient health status
at 3 months, measured using the EQ-5D health questionnaire, the Coronary
Revascularization Outcome Questionnaire (CROQ) (CABG patients only),
and the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
(AVR patients only). Blood samples for measuring lactate, pH, and serum
creatinine levels were taken at the same time points as for cTnT. Unex-
pected adverse events were coded using the Medical Dictionary for Regu-
latory Activities (version 14.1;McLean, Va). The evaluation of the effect of
propofol supplementation onmarkers of myocardial ischemic stress will be
reported separately.
Four secondary outcomes were removed from the protocol during the
study due to insufficient funding to complete the laboratory analyses. These
were concentration of microparticles in the circulation and measures of
systemic oxidative stress, inflammatory response, and renal injury.
Sample Size
The trial was designed to test a superiority hypothesis. A study of 96 pa-
tients (48 per group: 24 CABG and 24 AVR) was required to detect a dif-
ference of 0.5 standard deviations (SDs) between propofol and intralipid
supplementation within each surgical stratum with 80% power and 5%
significance (2-sided test). Each biomarker was measured at baseline and
5 times postintervention, and a correlation of 0.5 between repeated mea-
sures was assumed. No interaction between the treatment and surgical stra-
tum was anticipated.
Randomization and Blinding
The randomization scheme was stratified by operation (CABG or AVR)
and minimized by diabetes status (oral medication/insulin or not). A secure
internet-based system (http://www.sealedenvelope.com/) concealed allo-
cations until sufficient information to identify the participant had been
entered. Randomization took place after written informed consent had
been obtained, and as close to surgery as possible. Randomization was car-
ried out by staff not involved in data collection or patient care. Allocation
details and materials required for the intervention (bag of intralipid or vial
of propofol) were handed to the perfusionist in a sealed opaque envelope,
and removed from the operating theatre at the end of the procedure. The
required volume of emulsion was drawn-up in a syringe by the perfusionist
and added to the cardioplegia solution. Because intralipid emulsion is used
as a vehicle for propofol administration, the 2 interventions are visually
indistinguishable. All other staff remained blinded to the treatment alloca-
tion for the duration of the study.
Statistical Methods
Analyses were performed on an intention-to-treat basis and directed by
a prespecified statistical analysis plan. Continuous data are summarized as
mean  SD or median (interquartile range) if distributions are skewed.
Categorical data are summarized as number (percentage). Primary and sec-
ondary outcomeswere compared using logistic (binary variables), Cox pro-
portional hazards (time to event variables), or linear mixed model
(continuous variablesmeasured at multiple time points) regression, with in-
tralipid supplementation as the reference group. Model validity was
checked using standard methods; if a model fitted poorly, transformations
were explored. Outcomes analyzed on a logarithmic scale were trans-
formed back to the original scale after analysis and results presented as geo-
metric mean ratios (GMR). All analyses were adjusted for the stratification
and minimization variables, operation, and diabetes status. See the Online
Data Supplement for further details. The trial is not powered to detect dif-
ferences in clinical outcomes and their frequencies are tabulated descrip-
tively. Likelihood ratio tests were used to determine statistical significance.
Outcomes for CABG and AVR subgroups were compared by adding an
allocation 3 surgery interaction term into the models. A subgroup analysis
by diabetes status for the primary outcome was also prespecified.
Subgroup-specific effects are reported if the interaction termwas statistically
significant at the 10% level. Four sensitivity analyses were specified in the
analysis plan but not in the protocol (seeOnlineData Supplement for details).
All analyses were performed in SAS version 9.3 (SAS Institute Inc,
Cary, NC) and Stata version 13.0 (StataCorp LP, College Station, Tex).
RESULTS
Recruitment
Between March 2010 and July 2012, 203 patients were
screened for inclusion in the trial, 44 ofwhomwere ineligible.
Of the 159 eligible patients screened, 101 agreed to partici-
pate and were randomized; 51 to receive propofol and 50 to
receive intralipid (Figure 1). Two participants (1 allocated
to receive propofol and 1 allocated to receive intralipid)
were found to be ineligible during surgery because their left
ventricular function was worse than anticipated. However,
these participants consented for data collection to continue.
The primary analysis includes all randomized partici-
pants. There were 7 major protocol violations: 6 partici-
pants did not receive any trial treatment and 1 participant
allocated to the intralipid group received propofol (Tables
E1 and E2). Therefore, 95 participants were included in
the per-protocol analysis. Participants were followed for 3
months after randomization. Safety data at 3 months were
available on all participants and health status questionnaires
for 100 out of 101 participants.
Baseline Data
Themedian age of participants was 67.9 years (IQR, 63.9-
73.7 years) and 77 out of 101 (76%) were male (Table 1).
The median European System for Cardiac Operative Risk
Evaluation (version 1) score was 4 (IQR, 2-5). Overall, 61
out of 101 (60%) participants underwent CABG and 40
out of 101 (40%) participants underwent AVR surgery.
The majority of participants did not have diabetes (80 out
of 101; 79%). By chance, participants allocated to propofol
supplementation were slightly younger (median age, 66.5 vs
70.6 years) and included more current or exsmokers (34 out
of 51 [60%] vs 26 out of 50 [52%]) and more being treated
for hypertension (44 out of 51 [86%] vs 35 out of 50 [70%])
than participants allocated to intralipid. Medications before
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surgery are described in Table E3 and participant demo-
graphics by surgical stratum are given in Table E4.
Operative Details
Operative, crossclamp, and total bypass times were
similar in the 2 groups (Table 1). On average the surgery
took 3 hours 10 minutes and the duration of CPB was just
under 90 minutes. On average, total bypass time was 20 mi-
nutes longer for participants undergoing AVR compared
with CABG and the crossclamp timewas almost 30 minutes
longer, although the overall operation time was similar
(Table E5). Overall, 95 out of 101 (94%) participants
received tranexamic acid (median, 2 g in both groups) and
9 out of 101 (9%) required inotropic support (Table E6).
The majority of participants having CABG had  3 grafts
(22 out of 31 [71%] in the propofol group vs 23 out of 30
[77%] in the intralipid group). All participants received
blood cardioplegia. Both groups had circulating propofol
in the blood in the cardioplegia circuit due to the propofol
administered during anesthesia but, as expected, the mean
 SD concentration was higher in the propofol group
than in the intralipid group (9.92  1.38 vs 4.46  1.80
FIGURE 1. Participant flow. CABG, Coronary artery bypass grafting; AVR, aortic valve replacement; CPB, cardiopulmonary bypass; LV, left ventricular;
PIL, Patient Information Leaflet. *Patients may be ineligible for>1 reason. ySafety population identical to analysis population. zTwo participants (1 ran-
domized to propofol, 1 to intralipid) were withdrawn before surgery, but willing to continue with trial data collection. Both were found to be ineligible after
randomization.
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TABLE 1. Participant demographic characteristics and past history, intraoperative history, and postoperative details
Characteristic
Randomized to
propofol (n ¼ 51)
Randomized to
intralipid (n ¼ 50)
Overall
(n ¼ 101)
Demographic and past history
Age (y) 66.5 (62.5-72.1) 70.6 (65.0-76.4) 67.9 (63.9-73.7)
Male 41 (80) 36 (72) 77 (76)
Body mass index 29.3  5.6 27.1  3.8 28.2  4.9
Diabetic 11 (22) 10 (20) 21 (21)
Estimated glomerular filtration rate
(mL/min/1.73 m2)
69.9  20.0 72.2  14.8 71.0  17.6
Cardiac history
European System for Cardiac Operative
Risk Evaluation score
4 (2.0-5.0) 5 (3.0-6.0) 4 (2.0-5.0)
No. of vessels with coronary disease*
None 20 (39) 19 (38) 39 (39)
Single 1 (2) 2 (4) 3 (3)
Double 6 (12) 12 (24) 18 (18)
Triple 24 (47) 17 (34) 41 (41)
>50% disease in left main stem 9 (18) 5 (10) 14 (14)
Noncardiac history
Smoking status
Smoker 5 (10) 5 (10) 10 (10)
Nonsmoker 17 (33) 24 (48) 41 (41)
Exsmoker>1 mo 29 (57) 21 (42) 50 (50)
Family history 24 (47) 31 (62) 55 (54)
Hypertension requiring treatment 44 (86) 35 (70) 79 (78)
Stroke or transient ischemic attacks 2 (4) 4 (8) 6 (6)
Elective procedure 47 (92) 46 (92) 93 (92)
Intraoperative details
Operation duration (min) 191.0  32.2 190.1  29.7 190.5  30.8
Cumulative crossclamp time (min)y 54.0  19.7 53.4  16.2 53.7  18.0
Total bypass time (min)y 88.2  22.0 88.8  19.0 88.5  20.4
Myocardial protection
Concentration of propofol in cardioplegia
(mg/mL)z
9.92  1.38 4.46  1.80 7.16  3.17
Concentration of systemic (arterial line)
plasma propofol (mg/mL)
Before crossclampz 3.92  1.38 4.34  1.36 4.13  1.37
During crossclampz 4.16  1.20 4.36  1.23 4.26  1.21
10 min after crossclamp releasez 4.07  1.10 4.51  1.18 4.29  1.16
CABG surgery 31 (61) 30 (60) 61 (60)
No. of grafts
1 1 (3) 0 (0) 1 (2)
2 8 (26) 7 (23) 15 (25)
3 16 (52) 18 (60) 34 (56)
4 6 (19) 5 (17) 11 (18)
Estimated volume of cardioplegia
given (mL)x
1207  355 1197  333 1202  341
AVR surgery 20 (39) 20 (40) 40 (40)
Total volume of cold cardioplegia
given (mL)
1790.2  322.0 1782.4  264.1 1786.3  290.7
Postoperative details
Total ventilation time (h)jj 6.8 (4.9-8.8) 7.2 (5.6-10.5) 7.0 (5.2-8.8)
Time in intensive care unit (h){
CABG participants (n ¼ 61) 69.3 (47.8-113.0) 87.3 (68.0-114.0) 75.9 (49.0-113.0)
AVR participants (n ¼ 40) 89.5 (46.9-120.5) 47.0 (43.0-89.5) 49.0 (46.0-100.3)
(Continued)
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mg/mL). In contrast, the systemic propofol concentrations
in blood samples taken from the diagnostic radial arterial
line during aortic crossclamp were similar (mean difference
(MD), 0.02 mg/mL; 95% confidence interval (CI), 0.41
to 0.37; P ¼ .92), as were the propofol concentrations
in samples taken after crossclamp release (MD, 0.1
5mg/mL; 95% CI, 0.51 to 0.22; P ¼ .39).
Postoperative Outcomes
cTnT concentrations are illustrated in Figure 2 and
summarized in Table E7. Preoperative concentrations
were similar in the 2 groups (30 out of 50 [60%] below
the detectable limit, median concentration 21 ng/L
among participants with detectable concentrations in
the propofol group vs 34 out of 49 [69%] and 20 ng/L
in the intralipid group). cTnT concentrations rose
following surgery peaking at 6 hours and were, on
average, 15% lower in the propofol group (GMR, 0.85;
95% CI, 0.73-1.01; P ¼ .051). Average cTnT concentra-
tions were similar across the 2 surgical strata (test for
interaction P ¼ .36) and by diabetes status (Figure E1).
The preplanned sensitivity analysis did not alter the study
conclusions (Figure E2).
In contrast, postoperative lactate concentrations and
blood pH did not differ between the groups; lactate was,
on average, 7% higher in the propofol group (GMR, 1.07;
95% CI, 0.98-1.18; P ¼ .14) and the pH was slightly lower
(MD, 0.007; 95% CI, 0.018 to 0.003; P ¼ .17; Figure 3
and Table E8).
The effect of propofol supplementation on postopera-
tive renal function and on length of ICU/high depen-
dency unit stay differed between CABG and AVR
participants (test for interactions, P ¼ .069 and
P ¼ .068 for creatinine and ICU stay, respectively). Post-
operative creatinine concentrations were similar in the 2
groups for participants undergoing CABG (GMR,
1.010; 95% CI, 0.970-1.051; P ¼ .62), but higher in
the propofol group for participants undergoing AVR sur-
gery (GMR, 1.071; 95% CI, 1.019-1.125; P ¼ .007;
Figure 3 and Table E9). In participants who underwent
CABG the duration of ICU stay in the propofol group
tended to be shorter, whereas for participants undergoing
AVR surgery it was longer, but for both subgroups the
difference between the propofol and intralipid groups
was not statistically significant (CABG: median 69.3 vs
87.3 hours; hazard ratio (HR); 1.25; 95% CI, 0.75-
2.09; P ¼ .40 and AVR: median 89.5 vs 47.0 hours;
HR, 0.58; 95% CI, 0.31-1.09; P ¼ .09) (Table 1).
The surgery-specific health status scores, derived from
the CROQ, MLHFQ, and EQ-5D visual analog scale,
were similar in the propofol and intralipid groups (see
Figure E3 and Tables E10-E12). The proportion of
participants reporting perfect health on the EQ-5D (utility
score of 1) was similar in the 2 groups for participants
undergoing CABG surgery (12 out of 30 [40%] in
propofol group vs 9 out of 29 [31%] in the intralipid
group, odds ratio (OR) 1.31; 95% CI, 0.47-3.62;
P ¼ .61). However, of the participants undergoing
AVR surgery proportionally fewer had perfect health
in the propofol group (5 out of 20 [25%] vs 10 out of
TABLE 1. Continued
Characteristic
Randomized to
propofol (n ¼ 51)
Randomized to
intralipid (n ¼ 50)
Overall
(n ¼ 101)
Time on ward predischarge (h)# 73.5 (43.2-115.0) 92.8 (51.0-139.0) 91.0 (49.8-120.0)
Length of hospital stay (d) 7 (6-8) 6 (5-9) 6 (6-9)
Values are presented as median (interquartile range), mean  standard deviation, or n (%). Missing data (numbers for propofol and intralipid groups respectively): European
System for Cardiac Operative Risk Evaluation score: 2 (1,1). Cumulative crossclamp time, total bypass time, infusion mode and timing intermittent: 1 (1,0). Concentration
of propofol in cardioplegia solution: 6 (4,2). Concentration of systemic plasma propofol – before crossclamp: 6 (4,2); during crossclamp: 7 (4,3); 10 minutes after crossclamp
release: 6 (4,2). Estimated volume of cardioplegia given: 3 (3,0). CABG, Coronary artery bypass graft; AVR, aortic valve replacement. *One participant in the intralipid group
underwent aortic valve replacement and coronary artery bypass grafting. yOne participant in the propofol arm with crossclamp and bypass times missing because surgery per-
formed off-pump (see Table E1). zSix participants with systemic propofol concentration missing. They did not receive any intervention (see Table E1). xCardioplegia volume for
participants undergoing coronary artery bypass grafting is estimated using the time and the rate at which the cardioplegia solution was added to the cardiopulmonary bypass
circuit. jjTwo participants were reintubated (1 propofol [967 hours], and 1 intralipid [66.7 hours]). {One participant was excluded from the time in intensive care unit survival
analysis whose time in intensive care was 1419 hours (59 days). Participant’s stay was far greater than the time in intensive care for other participants in the study. #Three par-
ticipants in intralipid group were not admitted to the ward from the intensive care unit.
FIGURE 2. Cardiac troponin T response over time. Geometric mean and
95% confidence interval (CI) of cardiac troponin T level at each time point
and geometric mean ratio (GMR) for the effect of propofol versus intralipid
on cardiac troponin T release (95% CI). Pre-op, Preoperative; Post-op,
postoperative.
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19 [53%]; OR, 0.26; 95% CI, 0.06-1.05; P ¼ .058). The
test for interaction between treatment and surgery was
P ¼ .067. The sensitivity analysis, assuming missing
scores in MLHFQ indicated poor quality of life, was
consistent with the primary analyses (Figure E4).
Adverse Events
Overall, there were 211 postoperative complications (ie,
adverse events) in 87 participants; 99 complications in 44
out of 51 (86%) participants in the propofol group and
112 complications in 43 out of 50 (86%) participants in
the intralipid group (OR for 1 or more complications,
1.03; 95% CI, 0.33-3.21; P ¼ .95). Of these complica-
tions, 43 (26 propofol vs 17 intralipid) were classed as
SAEs. Twenty-two participants (11 in each group) experi-
enced one or more SAEs in the 3 months following sur-
gery (OR for 1 or more SAEs, 0.97; 95% CI, 0.36-2.56;
P ¼ .94). Of the 211 complications reported, 200 were ex-
pected (ie, they were listed in the study protocol) and 11
were unexpected. Ten of the 11 unexpected events were
classed as serious compared with 33 out of 200 (17%)
of expected events (Table 2). Additional details on the un-
expected events are given in Table E13. There were no
deaths. Event rates were similar across both groups for
the majority of complications. Participants in the intralipid
group were more likely to experience a pneumothorax or
pulmonary effusion requiring drainage (7 out of 50
[14%] vs 1 out of 51 [2%]) or an infective complication
(18 out of 50 [36%] vs 9 out of 51 [18%]). The differ-
ences in the frequencies of these complications were re-
flected in slightly longer intubation times and longer
ward stays in the intralipid group (median intubation
time, 6.8 vs 7.2 hours; median ward stay, 73.5 vs 92.8
hours) (Table 1).
DISCUSSION
We believe that this is the first randomized controlled
trial to evaluate the supplementation of propofol in cardio-
plegia solution in patients undergoing CABG or AVR sur-
gery. The study suggests that the addition of propofol to
the cardioplegia solution protects the heart against ischemic
reperfusion injury, as shown by the average 15% lower
cTnT release over the first 48 hours after surgery,
which equates to an average difference of between 60 and
90 ng/L across the first 48 hours. Previous studies have
suggested that troponin release is predictive of outcome.
Soraas and colleagues26 demonstrated that the long-term
mortality risk increases by 31% (95% CI, þ13%
to þ51%) for every 1 mg/L rise in peak cTnT and Mo-
hammed and colleagues27 suggested that cTnT is
FIGURE 3. Concentrations over time. A, Lactate (all participants). B, pH Levels (all participants), C, Creatinine (coronary artery bypass grafting [CABG]
participants). D, Creatinine (aortic valve replacement [AVR] participants). Geometric mean and 95% confidence interval (CI) at each study time point by
group, and geometric mean ratio (GMR) and 95% CI for the effect of propofol versus intralipid on lactate (all participants), creatinine (CABG participants),
and creatinine (AVR participants).Mean and standard deviation (SD) at each study time point by group, and mean difference (MD) and 95%CI for the effect
of propofol versus intralipid on pH level (all participants). Pre-op, Preoperative; Post-op, postoperative.
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TABLE 2. Postoperative complications
Event (expected or unexpected)
Randomized to propofol (n ¼ 51) Randomized to intralipid (n ¼ 50)
All events SAEs All events SAEs
Events/patients % Events/patients % Events/patients % Events/patients %
Any event (expected or unexpected) 99/44 86 26/11 22 112/43 86 17/11 22
Expected events listed in study protocol
Myocardial Infarction 2/2 4 1/1 2 0/0 0 0/0 0
Arrhythmias 30/24 47 4/3 6 33/26 52 0/0 0
Supraventricular tachycardia/atrial
fibrillation requiring treatment
25/21 41 3/2 4 24/24* 48 0/0 0
Ventricular fibrillation/ventricular
tachycardia requiring intervention
0/0 0 0/0 0 1/1 2 0/0 0
New pacing 5/5y 10 1/1 2 8/8y 16 0/0 0
Pacing permanent 1/1 2 1/1 2 0/0 0 0/0 0
Hemodynamic support 32/26 51 3/2 4 32/28 56 0/0 0
Inotropes used 17/16* 31 1/1 2 18/17* 34 0/0 0
Intra-aortic balloon pump used 1/1 2 1/1 2 0/0 0 0/0 0
Vasodilators used 13/13y 25 0/0 0 13/13y,z 26 0/0 0
Low cardiac output 1/1 2 1/1 2 1/1 2 0/0 0
Pulmonary complications 10/8 16 3/2 4 14/11 22 4/4 8
Reintubation/ventilation 1/1 2 1/1 2 1/1 2 0/0 0
Tracheostomy 1/1 2 1/1 2 0/0 0 0/0 0
Mask continuous positive airway
pressure
7/7 14 0/0 0 5/4 8 0/0 0
Pneumothorax or effusion requiring
drainage
1/1 2 1/1 2 8/7 14 4/4 8
Thromboembolic complications 1/1 2 1/1 2 1/1 2 1/1 2
Deep vein thrombosis 0/0 0 0/0 0 1/1 2 1/1 2
Pulmonary embolism 1/1 2 1/1 2 0/0 0 0/0 0
Infective complications 11/9y 18 3/3y 6 21/18y 36 4/4 8
Sepsis 5/4y 8% 0/0 0 13/11 23 0/0 0
Respiratory infection 5/5 10 0/0 0 12/10 20 0/0 0
New hemofiltration/dialysis 1/1 2 1/1 2 1/1 2 0/0 0
Gastrointestinal complications 5/5 10 4/4 8 2/2 4 2/2 4
Peptic ulcer/gastrointestinal bleed/
perforation
2/2 4 2/2 4 0/0 0 0/0 0
Other gastrointestinal complications 3/3 6 2/2 4 2/2 4 2/2 4
Permanent stroke 0/0 0 0/0 0 1/1y 2 1/1y 2
Wound dehiscence requiring reoperation 0/0 0 0/0 0 1/1 2 1/1 2
Chest reopened due to bleeding 0/0 0 0/0 0 2/2 4 0/0 0
Any expected event 92/43 84 20/10 20 108/43 86 13/10 20
Unexpected events not listed in study protocol
Bradycardia 0/0 0 0/0 0 1/1 2 1/1 2
Cardiac failure congestive 1/1 2 1/1 2 1/1 2 1/1 2
Chest pain 1/1 2 1/1 2 0/0 0 0/0 0
Cholecystectomy 0/0 0 0/0 0 1/1 2 1/1 2
Diverticulum 1/1 2 1/1 2 0/0 0 0/0 0
Maculopathy 1/1 2 1/1 2 0/0 0 0/0 0
Paraesthesia 0/0 0 0/0 0 1/1 2 1/1 2
Peripheral ischemia 1/1 2 1/1 2 0/0 0 0/0 0
Postprocedural hemorrhage 1/1 2 0/0 0 0/0 0 0/0 0
Renal failure acute 1/1 2 1/1 2 0/0 0 0/0 0
Any unexpected event 7/6 12 6/5 10 4/4 8 4/4 8
Serious adverse events postdischarge included for the propofol group: 2 gastrointestinal bleeds, 2 episodes of atrial fibrillation (1 participant), 1 myocardial infarction, 1 pneu-
mothorax, 1 pulmonary embolism, 1 infective complication, 1 diverticulum, 1 chest pain, 1 maculopathy, 1 congestive cardiac failure and 1 renal failure. Serious adverse events
postdischarge included for the intralipid group: 3 pneumothorax, 2 infective complications, 1 stroke, 1 cholecystectomy, and 1 congestive cardiac failure. Missing data (numbers
for propofol and intralipid groups respectively): Sepsis: 4 (1,3). SAE, Serious adverse event. *Two participants had study treatment discontinued. yOne participant had study
treatment discontinued. zOne participant received alternative treatment to that allocated.
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independently prognostic for death, heart failure, or need
for vasopressor agents (OR, 2.57; 95% CI, 1.9-3.4), with
a median cTnT of 1.01 ng/mL in those who did not
experience the outcome versus 1.6 ng/mL in those who did.
The data suggest a possible difference between the
CABG and AVR subgroups in the effect of propofol on
postoperative renal function, ICU stay, and health utility
status at 3 months: serum creatinine concentrations were
on average 7% higher in the propofol group in participants
undergoing AVR surgery, which equates to a difference of
approximately 30 mmol/L at 48 hours. Participants undergo-
ing AVR allocated to propofol stayed in the ICU on average
42 hours longer than those allocated to intralipid, and a
greater proportion had less-than-perfect health at 3 months.
These trends were not observed in the participants undergo-
ing CABG surgery.
It is possible that the differences observed for the AVR
group occurred by chance because the short half-life of pro-
pofol makes it difficult to give a plausible biological expla-
nation for differences arising  48 hours after leaving the
operating theatre. Alternatively, propofol, by lowering
blood pressure, may reduce renal perfusion and negatively
affect renal function. Also, the higher proportion of AVR
participants with risk factors for acute kidney injury allo-
cated to propofol supplementation may explain the differ-
ence. In particular, there were more participants with
chronic obstructive pulmonary disease, diabetes, hyperten-
sion, or female gender in the propofol group (17 out of 20
[85%] vs 15 out of 20 [75%])28 and the mean baseline esti-
mated glomerular filtration ratewas lower (62.8 vs 67.5 mL/
min/1.73m2).
Complications after cardiac surgery are common. The
majority of patients (86%) experienced at least 1 adverse
event, with similar numbers in the 2 groups. For 22
(22%) participants the event was classified as serious but
none led to death. This finding is in line with other trials;
the Titre-2 trial, which recruited 2000 participants, albeit
with a higher proportion of high-risk participants, reported
an SAE rate of 35%.29
The study has strengths and limitations. Strengths
include the inclusive eligibility criteria, with few patients
referred for isolated CABG or AVR surgery being ineli-
gible; avoidance of bias through concealed allocation, suc-
cessful blinding of participants, and the health care
personnel providing care; and use of an objective primary
outcome. The blood samples were analyzed in a single hos-
pital laboratory, thereby avoiding interlaboratory vari-
ability, and laboratory personnel conducting the analyses
were blinded to the group allocation.
With respect to limitations, the study was carried out in a
single center with a single surgeon and the study samplewas
small. During recruitment more patients were referred for
CABG than for AVR, which resulted in proportionally
more participants in the CABG than the AVR stratum,
reducing the power of the study to detect differences by sur-
gical stratum. Similarly, the study was underpowered to
detect differences in outcome between patients with and
without diabetes. There were some protocol deviations,
including 1 participant allocated to intralipid who had pro-
pofol supplementation and 6 participants who received
neither intervention; these deviations may have reduced
the differences between the groups.
Propofol is a general anesthetic widely used for the
induction and maintenance of anesthesia during cardiac
surgery.15 Its cardioprotective efficacy when used as an
anesthetic agent is inferior to standard volatile inhalational
anesthetics as shown in patients30 and in experimental
models.31 However, propofol is cardioprotective when
used at a relatively high maintenance dose in patients
undergoing CABG using CPB.32 A high dose of propofol
after isoflurane preconditioning also appears to confer
greater protection than isoflurane alone.33 The link bet-
ween propofol anesthesia and cardioprotection remains
controversial; recent research suggests that propofol anes-
thesia reduces the cardioprotection induced by remote
ischemic preconditioning.34,35
The concentration of propofol used in the study was rela-
tively low given that propofol supplementation of cardio-
plegia had not been investigated previously and the desire
to minimize any risk to participants. Substantially higher
cardioplegia supplementation is possible without exceeding
the systemic propofol concentration that is frequently expe-
rienced during induction and maintenance of general anes-
thesia with propofol. We consider the safety findings from
this trial reassuring and further study is warranted to inves-
tigate this promising intervention. It should include a range
of supplementation levels extending to a higher level than
used in our trial and test for a dose–response relationship.
CONCLUSIONS
Our study results suggest that propofol supplementation
protects the heart against ischemic reperfusion injury and
that its influence on early clinical outcomes may differ
between CABG and AVR surgery. A further study, using a
range of supplementation levels to explore dose–response
relationships, is the next step.
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SUPPLEMENTAL METHODS
Cardioplegia Composition and Delivery
Calafiore warm blood cardioplegia for coronary artery
bypass grafting (CABG). Potassium chloride (15%) 2 mmol po-
tassium ion/mL, magnesium sulphate (50%) 2 mmol magnesium ion/
mL, mixed in a potassium ion:magnesium ion 4:1 ratio.
A 60-mL syringe is prepared with 20 mL potassium chloride and 5 mL
magnesium sulfate and is loaded into a syringe driver. A roller pump draws
oxygenated blood from the oxygenator and the potassium/magnesium ion
mixture is added by syringe pump downstream. Intermittent antegrade de-
livery is used according to local protocol.
Cold blood cardioplegia for aortic valve replacement
(AVR). One liter Harefield Hospital Formulation (Ivex Pharmaceuti-
cals) containing: 8.6 g sodium chloride British Pharmacopoeia (BP),
6.252 g potassium chloride BP, 16.262 g magnesium chloride BP, 330
mg calcium chloride BP, and 1364 mg procaine hydrochloride BP.
In water for injections, also: 147 mmol sodium, 84 mmol potassium, 80
mmolmagnesium,2mmol calcium, 3mmolprocaine, and400mmol chloride.
A 500-mL prebagged solution was used. A roller pump drew oxygen-
ated blood from the oxygenator and the cardioplegia solution was added
in a 4:1 blood:cardioplegia ratio. Cold cardioplegia was given at a temper-
ature of approximately 4C and by either antegrade or retrograde delivery
(or a mixture of both) according to local protocol.
Anesthesia
Premed. 10-30 mg Temazepam 1-2 h before induction.
Induction. Midazolam; 5-10 mg/kg fentanyl; with or without propofol
up to 1 mg/kg, muscle relaxation as per standard practice.
Maintenance before cardiopulmonary bypass (CPB).
Isoflurane plus boluses of fentanyl as indicated (up to max 20 mg/kg).
Maintenance on CPB. Propofol target controlled infusion (TCI):
initial target 3 mg/mL (set according to the estimated ideal body weight)
titrated up/down to response.
Maintenance after CPB. Propofol TCI, converted to propofol
infusion (not target controlled) for transfer to cardiac intensive care.
Statistical Methods—Further Details
When analyzing continuous variables measured at baseline, the base-
line and posttreatment values were modeled jointly to avoid having to
exclude or impute cases with missing baseline measures. For the
analysis of myocardial troponin T (cTnT), a significant proportion of
participants had preoperative cTnT concentrations below the limit of
detection (14 ng/L), so the baseline cTnT was grouped into not detect-
able, detectable but below the median detectable value, or above the
median detectable value. This categorical variable was then fitted as a
covariate in the analysis model. EQ-5D utility scores were dichoto-
mized into ‘‘perfect health’’ (score ¼ 1) or ‘‘less than perfect health’’
(score<1) and compared using logistic regression; responses of almost
40% of participants at 3 months corresponded to a utility of 1, and
models analyzing utility as a continuously scaled variable did not fit
the data well.
There were 4 sensitivity analyses specified in the statistical analysis
plan. Two were for the primary outcome. One excluded participants
who did not receive either intervention and the other grouped partici-
pants by the treatment received (as opposed to treatment allocated).
The other 2 were for health status, in which one assumed missing re-
sponses to questions in the Minnesota Living with Heart Failure Ques-
tionnaire represent the worst possible outcome (the primary analysis
assumes missing responses represent no limitation on ability to com-
plete tasks) and the other included baseline data for the 1 participant
who completed the preoperative questionnaires retrospectively after
their operation.
Subgroup Analyses
A subgroup analysis was performed to investigate whether the effect of
propofol on troponin T release differed by diabetic status. The results of the
analysis are shown in Figure E1. There was no statistically significant dif-
ference in the effect of troponin between diabetic and nondiabetic partici-
pants (interaction term P value ¼ .54); however, the power to test for an
interaction is low. The estimates of the treatment effect in the 2 subgroups
are consistent with the overall analysis. The diabetic cohort is small (n ¼
21) and the confidence interval is wide.
Sensitivity Analyses
Primary outcome, Troponin T. The results of both sensitivity
analyses were consistent with the main analyses; troponin T levels were
lower in the propofol group, and of borderline statistical significance
(Figure E2).
Secondary outcomes. These sensitivity analyses did not change
the study conclusions (Figure E4). For the EQ-5D utility score, the
P value for the test of interaction between allocation and operation type
was .068.
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FIGURE E1. Effect of propofol on cardiac troponin T release by diabetes
status. GMR, Geometric mean ratio; CI, confidence interval.
FIGURE E2. Effect of propofol on troponin T release: sensitivity
analyses. GMR, Geometric mean ratio; CI, confidence interval.
FIGURE E3. Quality of life scores at 3 months. EQ-5D, EQ-5D health
questionnaire; VAS, visual analog scale; CROQ, Coronary Revascularisa-
tion Outcome Questionnaire; CABG, coronary artery bypass graft;
MLHFQ, Minnesota Living with Heart Failure Questionnaire; MD, mean
difference; OR, odds ratio; AVR, aortic valve replacement; CI, confidence
interval.
FIGURE E4. Effect of propofol on quality-of-life scores: sensitivity
analyses. EQ-5D, EQ-5D health questionnaire; VAS, visual analog scale;
CROQ, Coronary Revascularisation Outcome Questionnaire; CABG, coro-
nary artery bypass graft; MLHFQ, Minnesota Living with Heart Failure
Questionnaire; MD, mean difference; OR, odds ratio; AVR, aortic valve
replacement; CI, confidence interval.
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TABLE E1. Protocol deviations
Protocol deviation
Randomized to propofol (n ¼ 51) Randomized to intralipid (n ¼ 50) Overall (n ¼ 101)
n % n % n %
Participant received the alternative treatment to that
allocated
0/51 0 1/50 2 1/101 1
Did not meet the eligibility criteria but was treated 0/51 0 2/50 4 2/101 2
Deviated from the trial protocol for induction 1/51 2 1/50 2 2/101 2
Deviated from the trial protocol for maintenance on
cardiopulmonary bypass
4/51 8 6/50 12 10/101 10
Discontinuation of study treatment 4/51 8 2/50 4 6/101 6
Aortic valve repair participants only (n ¼ 20) (n ¼ 20) (n ¼ 40)
7.5 mL cardioplegia not replaced with 7.5 mL diluted
intralipid/propofol solution from the study
syringe during cold blood cardioplegia
0/20 0 1/19 5 1/39 3
Missing data (numbers for propofol and intralipid groups respectively): 7.5 mL cardioplegia not replace with 7.5 mL diluted intralipid/propofol solution from the study syringe
during cold blood cardioplegia: 1 (0, 1).
TABLE E2. Details of protocol deviations (where available)
Type of deviation Further details
Randomized to propofol
Deviated from the trial protocol for induction No misazolam given because had lorazepam premed
Deviated from the trial protocol for maintenance on CPB Propofol TCI titrated to 2 mg/mL due to low blood pressure
Deviated from the trial protocol for maintenance on CPB Propofol TCI titrated to 2 mg/mL due to hypotension
Deviated from the trial protocol for maintenance on CPB Propofol TCI titrated to 2-3 mg/mL
Deviated from the trial protocol for maintenance on CPB Propofol TCI titrated to 2 mg/mL to maintain blood pressure
Discontinuation of study treatment Surgeon changed postrandomization (operation performed off pump)
Discontinuation of study treatment Surgeon changed postrandomization
Discontinuation of study treatment Participant found to be ineligible during surgery (poor left ventricular
function) - withdrawn from treatment
Discontinuation of study treatment Temperature breach, drugs not suitable
Randomized to intralipid
Participant received the alternative treatment to that allocated Theatre slots switched, paperwork for other participant used in error
Did not meet the eligibility criteria but was treated Had AVR with or without ablation therefore not isolated AVR
Did not meet the eligibility criteria but was treated Scheduled for isolated AVR, but surgeon decided to also perform CABG
during procedure
Deviated from the trial protocol for induction >1 mg/kg propofol given - high blood pressure despite the above – 100 mg
total bolus
Deviated from the trial protocol for maintenance on CPB Propofol TCI titrated to 2 mg/mL due to hemodynamic response (ie, blood
pressure down)
Deviated from the trial protocol for maintenance on CPB Propofol TCI titrated to 2 mg/mL as clinically sufficient
Deviated from the trial protocol for maintenance on CPB Propofol TCI titrated down to 2 mg/mL due to low blood pressure
Deviated from the trial protocol for maintenance on CPB Propofol TCI titrated to 2.5 mg/mL - low blood pressure therefore higher
dose not given
Deviated from the trial protocol for maintenance on CPB Propofol TCI titrated to 2 mg/mL due to hypotension
Deviated from the trial protocol for maintenance on CPB Propofol TCI titrated to>3 mg/mL due to hypertension on CPB
Discontinuation of study treatment Swapped theatre, drugs not transferred
Discontinuation of study treatment Participant found to be ineligible during surgery (poor left ventricular
function) - withdrawn from treatment
7.5 mL cardioplegia not replaced with 7.5 mL diluted intralipid/propofol
solution from the study syringe during cold blood cardioplegia
25 mL intralipid solution
CPB, Cardiopulmonary bypass; TCI, target controlled infusion; CABG, coronary artery bypass grafting; AVR, aortic valve replacement.
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TABLE E3. Additional patient demographic information and past history
Characteristic Randomized to propofol (n ¼ 51) Randomized to intralipid (n ¼ 50) Overall (n ¼ 101)
Cardiac history
New York Heart Association functional class
I/asymptomatic 14 (27) 10 (20) 24 (24)
II 20 (39) 26 (52) 46 (46)
III 16 (31) 14 (28) 30 (30)
IV 1 (2) 0 (0) 1 (1)
Canadian Cardiovascular Society class
Asymptomatic 11 (22) 16 (32) 27 (27)
I 8 (16) 6 (12) 14 (14)
II 20 (39) 17 (34) 37 (37)
III 11 (22) 8 (16) 19 (19)
IV 1 (2) 3 (6) 4 (4)
Previous myocardial infarction 10 (20) 13 (26) 23 (23)
Myocardial infarction within past 90 d 3 (33) 7 (58) 10 (48)
Heart rhythm
Sinus 44 (88) 47 (94) 91 (91)
Atrial fibrillation/flutter 6 (12) 3 (6) 9 (9)
Noncardiac history
Hypercholesterolemia 37 (73) 39 (78) 76 (75)
Hypothyroidism 4 (8) 5 (10) 9 (9)
Preoperative tests
Hemoglobin (g/dL) 13.7  1.7 13.5  1.7 13.6  1.7
Platelets (3109/L) 221.2  53.6 232.1  63.9 226.6  58.9
Preoperative medications
Aspirin 35 (69) 35 (70) 70 (69)
Time aspirin stopped before surgery (d) 1.0 (1.0-2.0) 1.0 (1.0-1.0) 1.0 (1.0-2.0)
Clopidogrel 16 (31) 11 (22) 27 (27)
Time clopidogrel stopped before surgery (d) 6.0 (3.0-7.0) 8.0 (3.0-9.0) 6.5 (3.0-8.0)
Warfarin 4 (8) 3 (6) 7 (7)
Time warfarin stopped before surgery (d) 4.5 (4.0-5.5) 5.0 (4.0-5.0) 5.0 (4.0-5.0)
Heparin/clexane 1 (2) 2 (4) 3 (3)
Time heparin/clexane stopped before surgery (d) 2.0 (2.0-2.0) 2.0 (2.0-2.0) 2.0 (2.0-2.0)
Beta blockers 28 (55) 24 (48) 52 (51)
Calcium antagonists 16 (31) 11 (22) 27 (27)
Oral nitrates 7 (14) 9 (18) 16 (16)
Other lipid-lowering agents* 2 (4) 2 (4) 4 (4)
Statins 41 (80) 39 (78) 80 (79)
Angiotensin-converting enzyme inhibitors 27 (53) 22 (44) 49 (49)
Angiotensin II blockers 5 (10) 1 (2) 6 (6)
Diuretics 12 (24) 8 (16) 20 (20)
Digoxin 3 (6) 3 (6) 6 (6)
Antiarrhythmic 1 (2) 1 (2) 2 (2)
Values are presented as n (%), median (interquartile range), or mean  standard deviation. Missing data (numbers for propofol and intralipid groups respectively): myocardial
infarction within past 90 days: 2 (1, 1), heart rhythm: 1 (1, 0), time clopidogrel stopped before surgery: 1 (1, 0), time heparin/clexane stopped before surgery: 1 (0, 1). *Other lipid-
lowering agents used in propofol group for 2 participants (‘‘ezetimibe’’ and ‘‘5 mg bioprolol, 40 mg simvastatin, 400 mg nitromin spray, 10 mg ramapril’’). Other lipid-lowering
agents used in intralipid group for 2 participants (‘‘ezetimibe’’ and ‘‘160 mg fenofibrate’’).
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TABLE E4. Participant demographic characteristics and past history by surgical stratum
Characteristic
Corornary artery bypass grafting Aortic valve replacement
Randomized
to propofol
(n ¼ 31)
Randomized
to intralipid
(n ¼ 30)
Overall
(n ¼ 61)
Randomized
to propofol
(n ¼ 20)
Randomized
to intralipid
(n ¼ 20)
Overall
(n ¼ 40)
Age (y) 67.4 (63.7-72.1) 69.8 (63.8-76.4) 67.9 (63.8-73.7) 65.0 (61.8-70.4) 70.7 (66.1-76.5) 67.5 (64.3-74.3)
Male 28 (90) 26 (87) 54 (89) 13 (65) 10 (50) 23 (58)
Body mass index 29.6  5.4 27.1  4.2 28.4  5.0 28.9  6.1 27.2  3.2 28.1  4.9
Diabetic 9 (29) 9 (30) 18 (30) 2 (10) 1 (5) 3 (8)
Estimated glomerular filtration
rate* (mL/min/1.73 m2)
74.4  19.9 75.3  13.0 74.9  16.7 62.8  18.5 67.5  16.5 65.1  17.4
Cardiac history
European System for Cardiac
Operative Risk Evaluation score
3 (2.0-4.0) 4 (2.0-5.0) 3 (2.0-5.0) 4 (3.5-5.5) 6 (5.0-6.5) 5 (4.0-6.0)
New York Heart Association functional class
I/asymptomatic 8 (26) 7 (23) 15 (25) 6 (30) 3 (15) 9 (23)
II 14 (45) 17 (57) 31 (51) 6 (30) 9 (45) 15 (38)
III 8 (26) 6 (20) 14 (23) 8 (40) 8 (40) 16 (40)
IV 1 (3) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0)
Canadian Cardiovascular Society class
Asymptomatic 2 (6) 2 (7) 4 (7) 9 (45) 14 (70) 23 (58)
I 5 (16) 6 (20) 11 (18) 3 (15) 0 (0) 3 (8)
II 15 (48) 12 (40) 27 (44) 5 (25) 5 (25) 10 (25)
III 8 (26) 7 (23) 15 (25) 3 (15) 1 (5) 4 (10)
IV 1 (3) 3 (10) 4 (7) 0 (0) 0 (0) 0 (0)
Previous myocardial infarction 10 (32) 13 (43) 23 (38) 0 (0) 0 (0) 0 (0)
Myocardial infarction within last 90 d 3 (33) 7 (58) 10 (48) 0 (0) 0 (0) 0 (0)
Heart rhythm
Sinus 28 (90) 30 (100) 58 (95) 16 (84) 17 (85) 33 (85)
Atrial fibrillation/flutter 3 (10) 0 (0) 3 (5) 3 (16) 3 (15) 6 (15)
Coronary disease (No. of vessels)y
None 0 0 0 20 (100) 19 (95) 39 (98)
Single 1 (3) 1 (3) 2 (3) 0 (0) 1 (5) 1 (3)
Double 6 (19) 12 (40) 18 (30) 0 (0) 0 (0) 0 (0)
Triple 24 (77) 17 (57) 41 (67) 0 (0) 0 (0) 0 (0)
>50% disease in left main stem 9 (29) 5 (17) 14 (23) 0 (0) 0 (0) 0 (0)
Noncardiac history
Smoking status
Smoker 5 (16) 4 (13) 9 (15) 0 (0) 1 (5) 1 (3)
Nonsmoker 9 (29) 12 (40) 21 (34) 8 (40) 12 (60) 20 (50)
Exsmoker>1 mo 17 (55) 14 (47) 31 (51) 12 (60) 7 (35) 19 (48)
Family history 14 (45) 21 (70) 35 (57) 10 (50) 10 (50) 20 (50)
Hypertension requiring treatment 29 (94) 22 (73) 51 (84) 15 (75) 13 (65) 28 (70)
Hypercholesterolemia 25 (81) 29 (97) 54 (89) 12 (60) 10 (50) 22 (55)
Hypothyroidism 2 (6) 3 (10) 5 (8) 2 (10) 2 (10) 4 (10)
Stroke or transient ischemic attacks 2 (6) 2 (7) 4 (7) 0 (0) 2 (10) 2 (5)
Elective procedure 27 (87) 27 (90) 54 (89) 20 (100) 19 (95) 39 (98)
Preoperative tests
Hemoglobin (g/dL) 13.8  1.9 13.6  1.8 13.7  1.9 13.5  1.5 13.4  1.6 13.5  1.5
Platelets (3109/L) 218.5  43.4 226.6  59.1 222.4  51.4 225.4  67.5 240.3  71.3 232.8 68.9
Preoperative medications
Aspirin 28 (90) 29 (97) 57 (93) 7 (35) 6 (30) 13 (33)
Time aspirin stopped before surgery) (d) 1.0 (1.0-2.0) 1.0 (1.0-1.0) 1.0 (1.0-2.0) 1.0 (1.0-4.0) 1.0 (1.0-1.0) 1.0 (1.0-1.0)
Clopidogrel 15 (48) 11 (37) 26 (43) 1 (5) 0 (0) 1 (3)
Time clopidogrel stopped before surgery (d) 6.5 (5.0-7.0) 8.0 (3.0-9.0) 7.0 (5.0-8.0) 1.0 (1.0-1.0) 1.0 (1.0-1.0)
Warfarin 1 (3) 0 (0) 1 (2) 3 (15) 3 (15) 6 (15)
Time warfarin stopped before surgery(d) 6.0 (6.0-6.0) 6.0 (6.0-6.0) 4.0 (4.0-5.0) 5.0 (4.0-5.0) 4.5 (4.0-5.0)
(Continued)
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TABLE E4. Continued
Characteristic
Corornary artery bypass grafting Aortic valve replacement
Randomized
to propofol
(n ¼ 31)
Randomized
to intralipid
(n ¼ 30)
Overall
(n ¼ 61)
Randomized
to propofol
(n ¼ 20)
Randomized
to intralipid
(n ¼ 20)
Overall
(n ¼ 40)
Heparin/clexane 1 (3) 1 (3) 2 (3) 0 (0) 1 (5) 1 (3)
Time heparin/clexane stopped
before surgery (d)
2.0 (2.0-2.0) 2.0 (2.0-2.0) 2.0 (2.0-2.0)
Beta blockers 22 (71) 18 (60) 40 (66) 6 (30) 6 (30) 12 (30)
Calcium antagonists 12 (39) 8 (27) 20 (33) 4 (20) 3 (15) 7 (18)
Oral nitrates 7 (23) 8 (27) 15 (25) 0 (0) 1 (5) 1 (3)
Other lipid-lowering agentsz 1 (3) 2 (7) 3 (5) 1 (5) 0 (0) 1 (3)
Statins 29 (94) 29 (97) 58 (95) 12 (60) 10 (50) 22 (55)
Angiotensin-converting enzyme inhibitors 15 (48) 17 (57) 32 (52) 12 (60) 5 (25) 17 (43)
Angiotensin II blockers 4 (13) 0 (0) 4 (7) 1 (5) 1 (5) 2 (5)
Diuretics 5 (16) 3 (10) 8 (13) 7 (35) 5 (25) 12 (30)
Digoxin 1 (3) 0 (0) 1 (2) 2 (10) 3 (15) 5 (13)
Antiarrhythmic 0 (0) 1 (3) 1 (2) 1 (5) 0 (0) 1 (3)
Values are presented as median (interquartile range), n (%), or mean standard deviation. Missing data (numbers for coronary bypass grafting propofol, coronary bypass grafting
intralipid, aortic valve replacement propofol and aortic valve replacement intralipid groups respectively): European System for Cardiac Operative Risk Evaluation: 2 (1, 1, 0, 0),
myocardial infarction within past 90 days: 2 (1, 1, 0, 0), heart rhythm: 1 (0, 0, 1, 0), time clopidogrel stopped before surgery: 1 (1, 0, 0, 0), and time heparin/clexane stopped before
surgery: 1 (0, 0, 0, 1). *Baseline creatinine is reported in Table E9. yOne participant in the aortic valve replacement intralipid group had aortic valve replacement and coronary
bypass graft surgery—therefore the number of vessels for this participant is single, whereas all other aortic valve replacement participants have ‘‘none’’. zOther lipid-lowering
agents used in coronary artery bypass grafting propofol group for 1 participant (‘‘5 mg bioprolol, 40 mg simvastatin, 400 mg nitromin spray, and 10 mg ramapril’’). Other lipid-
lowering agents used in aortic valve replacement propofol group for 1 participant (‘‘ezetimibe’’). Other lipid-lowering agents used in coronary artery bypass grafting intralipid
group for 2 participants (‘‘ezetimibe’’ and ‘‘160 mg fenofibrate’’).
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TABLE E5. Intraoperative and postoperative details by surgical stratum
Intraoperative/postoperative
characteristic
Coronary artery bypass grafting Aortic valve replacement
Randomized
to propofol
(n ¼ 31)
Randomized
to intralipid
(n ¼ 30)
Overall
(n ¼ 61)
Randomized
to propofol
(n ¼ 20)
Randomized
to intralipid
(n ¼ 20)
Overall
(n ¼ 40)
Intraoperative details
Operation duration (min) 190.1  25.1 193.3  28.1 191.7  26.4 192.4  41.6 185.3  32.1 188.8  36.8
Cumulative crossclamp time (min)* 42.3  9.9 43.1  9.2 42.7  9.5 71.7  17.6 68.9  11.5 70.3  14.7
Total bypass time (min)* 79.4  17.6 80.6  17.4 80.0  17.3 101.3  21.7 101.1  14.6 101.2  18.2
Cardioplegia infusion mode*
Antegrade 30 (100) 30 (100) 60 (100) 5 (25) 4 (20) 9 (23)
Retrograde and antegrade 0 (0) 0 (0) 0 (0) 15 (75) 16 (80) 31 (78)
Intermittent infusion* 30 (100) 30 (100) 60 (100) 20 (100) 20 (100) 40 (100)
Concentration of propofol in blood in
cardioplegia circuit (mg/mL)y
9.72  1.32 4.73  2.01 7.22  3.03 10.2  1.43 4.08  1.42 7.07  3.41
Concentration of systemic (arterial
line) plasma propofol (mg/mL)
Before crossclampy 3.72  1.32 4.52  1.31 4.12  1.36 4.21  1.43 4.08  1.42 4.15  1.41
During crossclampy 4.11  1.24 4.39  0.92 4.25  1.10 4.24  1.16 4.32  1.57 4.28  1.37
10 min after crossclamp releasey 3.98  1.23 4.51  0.96 4.24  1.12 4.21  0.90 4.51  1.46 4.37  1.21
Blood saving techniques
Tranexamic acid 31 (100) 28 (93) 59 (97) 16 (80) 20 (100) 36 (90)
If yes, dose (g) 2.0 (2.0-4.0) 2.0 (2.0-2.0) 2.0 (2.0-2.7) 2.0 (2.0-4.1) 2.0 (2.0-4.3) 2.0 (2.0-4.1)
Pump blood given 28 (90) 30 (100) 58 (95) 17 (85) 20 (100) 37 (93)
If yes, pump blood washed 2 (7) 1 (4) 3 (5) 0 (0) 0 (0) 0 (0)
Inotropic support 4 (13) 2 (7) 6 (10) 2 (10) 1 (5) 3 (7.5)
Noradrenaline 3 (10) 0 (0) 3 (5) 1 (5) 1 (5) 2 (5)
Dobutamine 2 (6) 1 (3) 3 (5) 1 (5) 0 (0) 1 (3)
Dopamine 0 (0) 1 (3) 1 (2) 0 (0) 0 (0) 0 (0)
Enoximone 1 (3) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0)
Insulin infusion given after bypass 5 (16) 2 (7) 7 (11) 4 (20) 2 (10) 6 (15)
Intraoperative vasodilator used 0 (0) 3 (10) 3 (5) 3 (15) 2 (10) 5 (13)
Direct current shocks administered 2 (6) 2 (7) 4 (7) 5 (25) 1 (5) 6 (15)
Arrhythmia on chest closure
No, sinus rhythm only 28 (90) 29 (97) 57 (93) 17 (85) 16 (80) 33 (83)
Atrial flutter/fibrillation 2 (6) 0 (0) 2 (3) 2 (10) 2 (10) 4 (10)
Otherz 1 (3) 1 (3) 2 (3) 1 (5) 2 (10) 3 (8)
Pacing
None 29 (94) 28 (93) 57 (93) 15 (75) 14 (70) 29 (73)
Single chamber 1 (3) 0 (0) 1 (2) 4 (20) 4 (20) 8 (20)
Dual chamber 1 (3) 2 (7) 3 (5) 1 (5) 2 (10) 3 (8)
No additional drugs administered
intraoperatively
29 (100) 29 (100) 58 (100) 19 (100) 20 (100) 39 (100)
Postoperative details
HCT on return from theatre (%) 29.3 4.7 29.0  3.6 29.2  4.1 28.2  5.4 28.1  3.3 28.1  4.4
Temperature on return from theatre
(C)
36.4  0.5 36.2  0.5 36.3  0.5 35.9  0.5 35.8 0.3 35.9  0.4
Total ventilation time (h)x 6.6 (4.9-8.0) 7.4 (6.6-12.2) 7.2 (5.6-9.5) 6.8 (4.8-8.9) 6.7 (5.0-8.0) 6.8 (5.0-8.6)
Time on theward before discharge (h)jj 89.0 (51.0-120.0) 92.6 (49.8-141.5) 90.8 (51.0-137.0) 70.0 (26.5-106.3) 94.2 (71.0-116.7) 91.0 (46.3-114.3)
Length of hospital stay (d) 6.0 (5.0-9.0) 6.0 (6.0-9.0) 6.0 (5.0-9.0) 7.0 (6.0-7.0) 6.0 (5.0-9.0) 6.0 (6.0-8.0)
Values are presented as n (%), median (interquartile range), or mean  standard deviation. Missing data (numbers for coronary artery bypass grafting propofol, coronary artery
bypass grafting intralipid, aortic valve replacement propofol, and aortic valve replacement intralipid groups respectively): cumulative crossclamp time: 1 (1, 0, 0, 0), total bypass
time: 1 (1, 0, 0, 0), infusion mode: 1 (1, 0, 0, 0), timing intermittent: 1 (1, 0, 0, 0), concentration of propofol in cardioplegia solution: 6 (3, 2, 1, 0), concentration of systemic plasma
propofol – before crossclamp: 6 (3, 2, 1, 0) or during crossclamp: 7 (3, 3, 1, 0), 10 min after crossclamp release: 6 (3, 2, 1, 0), pump blood washed before given: 3 (0, 2, 1, 0),
additional drugs administered intraoperatively: 4 (2, 1, 1, 0). HCT, Hematocrit. *One participant in the coronary artery bypass grafting propofol arm with crossclamp and bypass
times, infusion mode and timing missing, because the surgery performed off-pump (Table E1). ySix participants with concentration of propofol missing as they did not receive any
intervention (Table E1). zOther arrhythmias in propofol group for 1 coronary artery bypass grafting participant (‘‘bradycardia requiring pacing for 48 h’’) and 1 aortic valve
replacement participant (‘‘heart block’’). Other arrhythmias in intralipid group for 1 coronary artery bypass grafting participant (‘‘paced’’) and 2 aortic valve replacement par-
ticipants (‘‘paced or sinus rhythm’’ and ‘‘block’’). xTwo coronary artery bypass grafting participants were reintubated (1 propofol [967 h], and 1 intralipid [66.7 h]). jjThree
coronary artery bypass grafting participants in the intralipid group were not admitted to the wards.
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TABLE E6. Additional intraoperative and postoperative details
Intra-operative/post-operative characteristic Randomized to propofol (n ¼ 51) Randomized to intralipid (n ¼ 50) Overall (n ¼ 101)
Intraoperative details
Cardioplegia infusion mode*
Antegrade 35 (70) 34 (68) 69 (69)
Retrograde and antegrade 15 (30) 16 (32) 31 (31)
Intermittent infusion* 50 (100) 50 (100) 100 (100)
Blood saving techniques
Tranexamic acid 47 (92) 48 (96) 95 (94)
If yes, dose (g) 2.0 (2.0-4.0) 2.0 (2.0-3.4) 2.0 (2.0-4.0)
Pump blood given 45 (88) 50 (100) 95 (94)
If yes, pump blood washed 2 (4) 1 (2) 3 (3)
Inotropic support 6 (12) 3 (6) 9 (9)
Noradrenaline 4 (8) 1 (2) 5 (5)
Dobutamine 3 (6) 1 (2) 4 (4)
Dopamine 0 (0) 1 (2) 1 (1)
Enoximone 1 (2) 0 (0) 1 (1)
Insulin infusion given post bypass 9 (18) 4 (8) 13 (13)
Intraoperative vasodilator used 3 (6) 5 (10) 8 (8)
Direct current shocks administered 7 (14) 3 (6) 10 (10)
Arrhythmia on chest closure
No, sinus rhythm only 45 (88) 45 (90) 90 (89)
Atrial flutter/fibrillation 4 (8) 2 (4) 6 (6)
Othery 2 (4) 3 (6) 5 (5)
Pacing 7 (14) 8 (16) 15 (15)
None 44 (86) 42 (84) 86 (85)
Single chamber 5 (10) 4 (8) 9 (9)
Dual chamber 2 (4) 4 (8) 6 (6)
No additional drugs administered intraoperatively 48 (100) 49 (100) 97 (100)
Conduit graft type (coronary artery bypass
grafting participants only)z
Saphenous vein 57 (64) 55 (63) 112 (63)
Radial artery 3 (3) 3 (3) 6 (3)
Left internal thoracic artery 28 (31) 28 (32) 56 (32)
Right internal thoracic artery 1 (1) 2 (2) 3 (2)
Postoperative details
HCT on return from theatre (%) 28.9  4.9 28.6  3.5 28.8  4.3
Temperature on return from theatre (C) 36.2  0.5 36.0  0.5 36.1  0.5
Values are presented as median (interquartile range), n (%), or mean  standard deviation. Missing data (numbers for propofol and intralipid groups respectively): pump blood
washed before given: 3 (0, 3), and additional drugs administered intraoperatively: 4 (3, 1). HCT, Hematocrit. *One participant in the propofol arm with infusion mode and timing
missing because surgery performed off-pump (see Table E1). yOther arrhythmias in the propofol group for 2 participants (‘‘bradycardia requiring pacing for 48 h’’ and ‘‘heart
block’’). Other arrhythmias in the intralipid group for 3 participants (‘‘paced,’’ ‘‘paced or sinus rhythm,’’ and ‘‘block’’). zOne hundred seventy-seven grafts used across all par-
ticipants (n ¼ 89 in the propofol group, n ¼ 88 in the intralipid group).
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TABLE E7. Troponin T (ng/L) concentrations
Troponin T sample time
Randomized to
propofol (n ¼ 51)
Randomized to
intralipid (n ¼ 50)
Preoperative
<14 ng/L 30 (60) 34 (69)
14 ng/L 20 (40) 15 (31)
Preoperative ( 14 ng/L only) 21.0 (15.0-24.0) 20.0 (15.0-29.0)
After chest closure (h)
1 393.0 (298.0-597.0) 486.0 (360.0-571.0)
6 552.0 (396.0-827.0) 616.5 (492.5-704.0)
12 434.0 (350.5-651.5) 497.0 (419.0-607.0)
24 385.0 (263.0-448.0) 395.0 (300.0-507.3)
48 302.7 (211.0-378.0) 280.5 (222.0-367.0)
Data are presented as n (%) or median (interquartile range). Missing data (numbers
for propofol and intralipid groups respectively): preoperative: 2 (1, 1), after chest
closure: 1 h: 1 (0, 1), 6 h: 2 (0, 2), 12 h: 4 (3, 1), 24 h: 2 (1, 1); 48 h: 3 (1, 2).
TABLE E8. Lactate concentrations (mmol/L) and pH levels
Lactate/pH sample time
Lactate pH
Randomized to propofol
(n ¼ 51)
Randomized to intralipid
(n ¼ 50)
Randomized to propofol
(n ¼ 51)
Randomized to intralipid
(n ¼ 50)
Preoperative 0.8 (0.5-1.1) 0.8 (0.6-1.0) 7.416  0.031 7.426  0.039
After chest closure (h)
1 1.2 (0.9-1.4) 1.0 (0.7-1.1) 7.373  0.047 7.369  0.058
6 1.1 (0.9-1.6) 1.1 (0.8-1.4) 7.339  0.046 7.347  0.054
12 1.5 (1.0-1.7) 1.2 (1.0-1.5) 7.339  0.047 7.351  0.055
24 1.3 (1.1-1.8) 1.2 (1.0-1.6) 7.336  0.044 7.351  0.048
48 1.2 (0.9-1.5) 1.2 (1.0-1.6) 7.356  0.041 7.367  0.060
Values are presented as median (interquartile range) or mean standard deviation. Missing data (numbers for propofol and intralipid groups respectively): lactate preoperatively:
1 (1, 0), lactate after chest closure: 1 h: 2 (1, 1), 6 h: 1 (1, 0), 12 h: 1 (1, 0), 24 h: 5 (2, 3), 48 h: 23 (9, 14), and pH after chest closure: 1 h: 1 (0, 1), 12 h: 1 (1, 0), 24 h: 5 (2, 3), 48 h: 25
(11, 14).
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TABLE E9. Renal function, measured by serum creatinine (mmol/L), by surgical stratum
Serum creatinine
sample time
Coronary artery bypass grafting Aortic valve replacement
Randomized to propofol
(n ¼ 31)
Randomized to intralipid
(n ¼ 30)
Randomized to propofol
(n ¼ 20)
Randomized to intralipid
(n ¼ 20)
Preoperative 88.0 (74.0-105.0) 88.0 (78.0-92.0) 88.5 (81.5-106.5) 83.5 (72.0-95.5)
After chest closure (h)
1 91.0 (77.0-98.0) 84.0 (78.0-96.0) 95.0 (85.5-111.5) 83.5 (67.0-91.0)
6 96.0 (81.0-113.0) 90.5 (82.0-100.0) 101.0 (94.0-119.0) 90.5 (78.0-96.0)
12 98.0 (85.0-112.0) 94.0 (85.0-102.0) 115.0 (97.0-127.0) 94.0 (82.0-109.0)
24 110.0 (90.0-147.0) 97.0 (90.5-118.0) 129.0 (107.0-157.0) 92.5 (77.0-111.0)
48 112.0 (87.0-165.0) 97.0 (81.0-114.5) 119.0 (104.0-145.0) 88.5 (80.0-115.5)
Values are presented as median (interquartile range). Missing data (numbers for coronary artery bypass grafting propofol, coronary artery bypass grafting intralipid, aortic valve
replacement propofol and aortic valve replacement intralipid groups respectively): preoperative: 1 (0, 1, 0, 0) and after chest closure: 1 h: 1 (0, 1, 0, 0), 6 h: 3 (0, 2, 1, 0), 12 h: 4 (2,
1, 1, 0), 24 h: 4 (0, 2, 2, 0), and 48h: 3 (1, 2, 0, 0).
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TABLE E10. Quality-of-life scores
Measure
Randomized
to propofol
Randomized
to intralipid
EQ-5D VAS (n ¼ 51) (n ¼ 50)
Preoperative 68  21.0 66  20.8
3 mo postoperative 77  19.2 80  12.4
CROQ (n ¼ 31) (n ¼ 30)
Core total score
Preoperative 50.0 (44.3-54.8) 52.1 (44.9-57.7)
3 mo postoperative 51.6 (45.9-55.6) 52.9 (48.1-55.0)
Symptoms score
Preoperative 67.9 (54.7-85.7) 78.6 (50.0-89.9)
3 mo postoperative 94.7 (82.1-100.0) 96.4 (91.7-100.0)
Physical functioning score
Preoperative 75.0 (50.0-87.5) 68.8 (40.7-96.9)
3 mo postoperative 81.3 (68.8-100.0) 87.5 (75.0-100.0)
Cognitive functioning score
Preoperative 80.0 (60.0-93.3) 86.7 (66.7-93.3)
3 mo postoperative 90.0 (66.7-100.0) 86.7 (73.3-100.0)
Psychosocial functioning score
Preoperative 65.9 (51.8-85.7) 73.2 (53.6- 91.1)
3 mo postoperative 86.6 (67.9-96.4) 87.5 (75.0-94.6)
Satisfaction score
3 mo postoperative 84.7 (72.2-95.8) 83.3 (72.2-95.8)
Adverse events score
3 mo postoperative 89.8 (70.5-95.5) 87.5 (79.5-95.5)
MLHFQ (n ¼ 20) (n ¼ 20)
Overall score
Preoperative 28.5 (11.0-54.0) 27.0 (11.0-35.5)
3 mo postoperative 15.0 (5.0-32.0) 12.5 (3.0-29.0)
Physical dimension score
Preoperative 15.5 (5.5-24.0) 16.0 (8.5-21.0)
3 mo postoperative 8.0 (3.0-16.0) 6.0 (1.0-15.0)
Emotional dimension score
Preoperative 4.5 (1.5-12.5) 4.0 (1.5-8.0)
3 mo postoperative 3.0 (0.0-8.0) 4.0 (0.0-7.0)
Values are presented as mean  standard deviation or median (interquartile range).
Missing data (numbers for propofol and intralipid groups, respectively): EQ-5D
VAS score preoperatively: 1 (0, 1), EQ-5D VAS score postoperatively: 2 (1, 1),
CROQ core score preoperatively: 1 (0, 1), CROQ core score postoperatively: 1 (1,
0), CROQ symptoms score preoperatively: 1 (0, 1), CROQ symptoms score postop-
eratively: 2 (1, 1), CROQ physical functioning score preoperatively: 2 (0, 2), CROQ
physical functioning score post-operatively: 2 (1, 1), CROQ cognitive functioning
score preoperatively: 1 (0, 1), CROQ cognitive functioning score postoperatively: 1
(1, 0), CROQ psychological functioning score preoperatively: 1 (0, 1), CROQ psy-
chological functioning score postoperatively: 1 (1, 0), CROQ satisfaction score post-
operatively: 1 (1, 0), CROQ adverse events score postoperatively: 1 (1, 0), MLHFQ
overall score postoperatively: 1 (1, 0), MLHFQ physical dimension score postopera-
tively: 1 (1, 0), MLHFQ emotional dimension score postoperatively: 1 (1, 0). VAS,
Visual analog scale; CROQ, Coronary Revascularization Outcome Questionnaire;
MLHFQ, Minnesota Living with Heart Failure Questionnaire.
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TABLE E11. EQ-5D utility score by surgical stratum
EQ-5D questionnaire
time point
Coronary artery bypass grafting Aortic valve replacement
Randomized to
propofol (n ¼ 31)
Randomized to
intralipid (n ¼ 30)
Randomized to
propofol (n ¼ 20)
Randomized to
intralipid (n ¼ 20)
Preoperative 0.796 (0.689-1.000) 0.727 (0.620-0.850) 0.867 (0.638-1.000) 0.760 (0.620-1.000)
3 mo postoperative 0.814 (0.727-1.000) 0.796 (0.689-1.000) 0.788 (0.586-0.925) 1.000 (0.691-1.000)
Values are presented as median (interquartile range). Missing data (numbers for coronary artery bypass grafting propofol, coronary artery bypass grafting intralipid, aortic valve
replacement propofol, and aortic valve replacement intralipid groups, respectively): EQ-5D utility score preoperatively: 3 (1, 1, 0, 1) and EQ-5D utility score postoperatively: 3 (1,
1, 0, 1).
TABLE E12. EQ-5D categorical responses
Category
Baseline 3 mo postoperation
Randomized
to propofol (n ¼ 51)
Randomized
to intralipid (n ¼ 50)
Randomized
to propofol (n ¼ 51)
Randomized
to intralipid (n ¼ 50)
Mobility
No problems 34 (67) 24 (50) 32 (64) 35 (71)
Some problems 17 (33) 22 (46) 16 (32) 14 (29)
Confined to bed 0 (0) 2 (4) 2 (4) 0 (0)
Self-care
No problems 46 (90) 45 (94) 45 (90) 45 (92)
Some problems 5 (10) 2 (4) 4 (8) 4 (8)
Unable to wash/dress 0 (0) 1 (2) 1 (2) 0 (0)
Usual activities
No problems 25 (49) 25 (52) 30 (60) 28 (57)
Some problems 20 (39) 21 (44) 18 (36) 21 (43)
Unable to perform usual activities 6 (12) 2 (4) 2 (4) 0 (0)
Pain/discomfort
No pain/discomfort 28 (55) 23 (48) 27 (54) 25 (51)
Moderate pain/discomfort 21 (41) 25 (52) 21 (42) 21 (43)
Extreme pain/discomfort 2 (4) 0 (0) 2 (4) 3 (6)
Anxiety/depression
Not anxious/depressed 36 (72) 27 (56) 40 (80) 34 (71)
Moderately anxious/depressed 14 (28) 18 (38) 9 (18) 14 (29)
Extremely anxious/depressed 0 (0) 3 (6) 1 (2) 0 (0)
Missing data (numbers for propofol baseline, propofol postoperation, intralipid baseline, and intralipid postoperative groups respectively): mobility: (0, 1, 2, 1), self-care: (0, 1, 2,
1), usual activities: (0, 1, 2, 1), pain/discomfort: (0, 1, 2, 1), and anxiety/depression: (1, 1, 2, 2).
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TABLE E13. Further details on unexpected serious adverse events (SAEs) and deaths
Study ID
Randomized
allocation Event Timing of SAE
Maximum
intensity Relatedness Reason event SAE
1 Propofol Diverticulum Postdischarge Moderate Unlikely to
be related
Event resulted in
hospitalization
2 Propofol Peripheral
ischemia
Presurgery Moderate Unlikely to
be related
Event resulted in persistent/
significant disability/
incapacity
3 Propofol Chest pain Postdischarge Severe Not related Event resulted in persistent/
significant disability/
incapacity
AND hospitalization
4 Intralipid Bradycardia Postsurgery but
predischarge
Moderate Unlikely to
be related
Event prolonged ongoing
hospitalization
5 Intralipid Cholecystectomy Postdischarge Moderate Not related Event resulted in persistent/
significant disability/
incapacity
AND hospitalization
6 Intralipid Cardiac failure
congestive
Postdischarge Severe Unlikely to
be related
Event resulted in
hospitalization
7 Propofol Maculopathy Postdischarge Moderate Unlikely to
be related
Event resulted in persistent/
significant disability/
incapacity
8 Intralipid Paraesthesia Postsurgery but
predischarge
Moderate Unlikely to
be related
Event resulted in persistent/
significant disability/
incapacity
9 Propofol Cardiac failure
congestive
Postdischarge Severe Unlikely to
be related
Event resulted in
hospitalization
Renal failure
acute
Postdischarge Severe Unlikely to
be related
Event resulted in
hospitalization
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